



NUCLEABIOMARKERS

For Further Information Contact

Patrick J. Muraca, President and CEO

PRESS RELEASE

Nuclea Biomarkers, LLC

105 South Street

Pittsfield, MA 01201

Phone 413-749-4705

Fax: 413-445-9930

Email: pr@nucleabiomarkers.com

www.nucleabiomarkers.com

FOR IMMEDIATE RELEASE

NUCLEA BIOMARKERS ANNOUNCES THE DEVELOPMENT AND PRODUCTION OF TMA MICROARRAYS BY AUTOMATED METHODOLOGY

Pittsfield, Massachusetts.....November 20st, 2006.....Nuclea Biomarkers, LLC

announced today that it has invested in new technology for the production of TMA Microarrays. Nuclea has purchased an Automated TMA Microarray Instrument from Beecher Instruments, Inc. located in Sun Prairie, Wisconsin. The Instrument, ATA-27 automated arrayer is designed for the construction of high-density TMA Microarray blocks fast, accurate and reliable. The instrument can accommodate all current tissue cassettes and can be easily adapted to array large or odd-shaped archival specimens. Nuclea has added two additional full time employees to operate the instrument in two specific production shifts.

Nuclea will still produce TMA Microarrays by its proprietary manual methodology for special situations, such as custom or difficult array development. “ This new automated methodology for the production of TMA Microarrays allows to the company to expand its production by approximately 75% of its current production rate, states Patrick Muraca, President and CEO. “TMA Microarray development, along with the Microfluidic Array Development is core to achieving our research and revenue goals for 2007” stated Muraca.

Nuclea Biomarkers, LLC has made an investment of approximately \$200,000 in this new automated technology.

Nuclea Biomarkers, LLC is a biotechnology services company that has developed a novel technology platform to greatly improve the efficiency of genomics, pharmacogenomics and drug discovery research. Using the company's extensive and growing libraries of genetic, molecular and clinical information, research professionals in pharmaceutical, diagnostic and other life-sciences companies are able to focus time and money on the most promising paths for diagnosing and treating a broad range of diseases.